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Abstract
The mammalian natural killer gene complex (NKC) contains several families of
type II transmembrane C-type lectin-like receptors (CLRs) that are best known for
their involvement in the detection of virally infected or transformed cells, through
the recognition of endogenous (or self) proteinacious ligands. However, certain
CLR families within the NKC, particularly those expressed by myeloid cells,
recognize structurally diverse ligands and perform a variety of other immune and
homoeostatic functions. One such family is the ‘Dectin-1 cluster’ of CLRs, which
includes MICL, CLEC-2, CLEC12B, CLEC9A, CLEC-1, Dectin-1 and LOX-1. Here,
we review each of these CLRs, exploring our current understanding of their ligands
and functions and highlighting where they have provided new insights into the
underlying mechanisms of immunity and homeostasis.
Introduction
C-type lectins are a superfamily of proteins that contain one
or more C-type lectin-like domains (CTLDs), and have been
divided into 17 groups based on their phylogeny and domain
organization (Zelensky & Gready, 2005). The CTLD consists
of a distinctive protein fold that is generated through
disulﬁde linkages between conserved cysteine residues, but
despite the similarity in structure, these domains recognize
diverse and structurally unrelated ligands. These receptors
can be loosely classiﬁed as ‘classical’ and ‘nonclassical’ C-
type lectins based on their ability to recognize carbohydrate
and noncarbohydrate ligands, respectively. In addition,
these receptors can be either membrane bound or soluble,
being secreted from cells into the extracellular milieu.
Of particular interest are the group V transmembrane
C-type lectins encoded within the natural killer gene complex
(NKC), onhuman chromosome 12and mousechromosome
6, which are best known for their recognition of endogenous
proteinacious ligands and involvement in the detection of
virally infected or transformed cells (Yokoyama & Plougastel,
2003). However, some CLR subfamilies, especially those
expressed by myeloid cells, recognize structurally diverse
ligands and perform a variety of other immune and homo-
eostatic functions, and are often encoded within a single
gene cluster. One such subfamily is the ‘Dectin-1 cluster’
which is primarily, but not exclusively, expressed by myeloid
cells [macrophages, dendritic cells (DC) and neutrophils]
(Fig.1).These type IItransmembrane receptors,which include
MICL, CLEC-2, CLEC12B, CLEC9A, CLEC-1, Dectin-1 and
LOX-1, comprise a single extracellular CTLD, a stalk region
of variable length and a cytoplasmic tail containing various
signaling motifs (Fig. 2). Here, we will brieﬂy review each
of these CLRs in the order they are found in the genome
(Fig. 1), highlighting their roles in immunity and home-
ostasis. A summary of the functions, ligands and expression
of each receptor is shown in Table 1.
Myeloid inhibitory C-type lectin-like
receptor (MICL) (CLEC12A)
MICL was originally identiﬁed by homology to Dectin-1
and its position within the Dectin-1 cluster (Marshall et al.,
2004). MICL was subsequently identiﬁed by three other
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dendritic-cell-associated C-type lectin 2 (DCAL-2) and kill-
er cell lectin-like receptor 1 (KLRL1) (Bakker et al., 2004;
Han et al., 2004; Chen et al., 2006). Human MICL is variably
spliced, generating at least three isoforms, and highly
N-glycosylated, and although it contains cysteine residues
in its stalk region, the receptor appears to be expressed as
a monomer. Murine MICL, however, is expressed as a
dimer and is not heavily glycosylated (Pyz et al., 2008).
Both murine and human MICL are predominantly
expressed by myeloid cells (granulocytes, monocytes,
macrophages and DCs) and expression of this receptor is
downregulated following inﬂammatory conditions, includ-
ing those triggered by microbial components (Marshall
et al., 2004, 2006; Pyz et al., 2008). In humans, MICL has
been identiﬁed as a marker for acute myeloid leukemia
(Bakker et al., 2004).
MICL contains a single ITIM in its cytoplasmic tail that
can associate with the signaling phosphatases SHP-1 and
SHP-2 (Han et al., 2004; Marshall et al., 2004; Pyz et al.,
2008), and is able to inhibit cellular activation (Marshall
et al., 2004). MICL has also been reported to inhibit NK cell
cytotoxicity (Han et al., 2004), although the receptor is not
expressed on NK cells (Marshall et al., 2006), and antibody-
mediated cross-linking of MICL on human monocyte-
derived DCs has been shown to affect DC function, by
altering cytokine production, cellular maturation and che-
mokine receptor expression, suggesting a role for this
receptor in the control of immune responses (Chen et al.,
2006). However, the mechanisms and signiﬁcance of these
effects are unclear. Recently murine MICL was shown to
recognize an endogenous ligand that was present in many
tissues, suggesting that the receptor may also play a role in
Fig. 2. Cartoon representation of the typical structure of group V CLRs.
Dectin-1 and MICL are shown as representatives of activation and
inhibitory receptors that are found in this cluster. Proximal signaling
components are also indicated. Lollipop structures indicate sites of
N-linked glycosylation.
Table 1. Selected ligands and expression proﬁles of the Dectin-1 cluster of C-type lectin receptors
Ofﬁcial name Alternate names Cellular expression (human) Exogenous ligands Endogenous ligands Cellular function
CLEC12A MICL, DCAL2,
CLL1, KLRL1
Myeloid cells ? Yes but identity unknown Inhibition
CLEC1B CLEC-2 Platelets
Myeloid cells?
Rhodocytin, HIV Podoplanin Activation
CLEC12B Macrophage
antigen H
Macrophages ? ? Inhibition
CLEC9A DNGR1 BDCA3
1 DC,
monocyte subsets, B-cells
? ? Activation
CLEC1A CLEC-1 DC ? ? ?
CLEC7A Dectin-1 Myeloid cells, T-cell subsets,
B cells, mast cells, eosinophils
b-Glucan,
Mycobacterial ligand
T-cells
Apoptotic cells
Activation
CLEC8A LOX-1 Endothelium, smooth muscle,
platelets, ﬁbroblasts, macrophages
Gram-positive
Gram-negative bacteria
ox-LDL
modiﬁed lipoprotiens
Aged/apoptotic cells
Advanced glycation
end-products
HSP70
Activation
‘?’ refers to unknown data.
Fig. 1. Cartoon representation of the genomic organization of the
‘Dectin-1 cluster’ in the NKC on human chromosome 12. Activation
receptors are shown in light grey, inhibitory receptors in dark grey, and
those whose function is unclear are shown in white.
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determined (Pyz et al., 2008).
CLEC-2 (CLEC1B)
CLEC-2 was identiﬁed from a computational screen for
CLRs at the same time as CLEC-1 (discussed below)
(Colonna et al., 2000). The expression of CLEC-2 has been
described on platelets, megakaryocytes and liver sinusoidal
endothelial cells, although reverse transcriptase (RT)-PCR
analysis indicates that the receptor may also be expressed on
monocytes, DC and granulocytes (Colonna et al., 2000;
Chaipan et al., 2006; Suzuki-Inoue et al., 2006). CLEC-2 is
differentially glycosylated and, in mouse, is expressed in at
least three isoforms, which are generated by alternative
splicing and which possess different expression proﬁles and
subcellular localizations (Suzuki-Inoue etal., 2006;Xie etal.,
2008). Furthermore, full-length mCLEC-2 is proteolytically
cleaved from the membrane, generating a soluble homo-
dimeric form (Xie et al., 2008).
Activation of CLEC-2 triggers platelet activation and
aggregation, an activity that is mediated by the cytoplasmic
immunoreceptor tyrosine-based activation (ITAM)-like
motif of CLEC-2 (Suzuki-Inoue et al., 2006). This single
tyrosine-based motif is highly similar to that found in
Dectin-1, and can recruit and signal via spleen tyrosine
kinase (Syk) (Suzuki-Inoue et al., 2006). In addition to Syk,
Tec family kinases, Src, PLCg and Rac1 have been implicated
in the signaling pathway activated by CLEC-2 (Fuller et al.,
2007; Pleines et al., 2008).
A number of endogenous and exogenous ligands for
CLEC-2 have been identiﬁed, including the snake venom
toxin, rhodocytin (Suzuki-Inoue et al., 2006). Rhodocytin
assembles as a tetramer and it is thought that recognition by
CLEC-2 induces clustering of the receptor, triggering down-
stream signaling and platelet activation (Watson et al., 2007,
2008; Hooley et al., 2008). CLEC-2 can also bind HIV-1, and
may capture and transfer infectious HIV-1 in cooperation
with DC-SIGN (dendritic cell-speciﬁc intercellular adhesion
molecule-3-grabbing non-integrin) (Chaipan et al., 2006).
One endogenous ligand, podoplanin, has also been
identiﬁed for CLEC-2 (Suzuki-Inoue et al., 2007). Podopla-
nin is a mucin-type sialoglycoprotein that is expressed on a
variety of cell types, but not on blood vessel endothelium,
and has been implicated in tumor cell-induced platelet
aggregation, tumor metastasis and lymphatic vessel forma-
tion. It has been suggested that the interaction of CLEC-2
with podoplanin, which involves O-glycans, may be in-
volved in promoting tumor growth and/or metastasis, and
could therefore be a target for therapeutic intervention
(Suzuki-Inoue et al., 2007; Christou et al., 2008; Kato et al.,
2008). Despite the identiﬁcation of all these ligands, how-
ever, the physiological role of CLEC-2 is still unknown.
CLEC12B
Little is known about CLEC12B, which was identiﬁed in the
Dectin-1 cluster through computational analysis (Sobanov
et al., 2001). RT-PCR analysis has indicated that human
CLEC12B is widely expressed at low levels in various human
tissues, except the brain, and that the receptor is alterna-
tively spliced, generating at least two isoforms, one of which
lacks part of the carbohydrate recognition domain (CRD)
and would be predicted to be nonfunctional (Hoffmann
et al., 2007). This nonfunctional isoform appears to be
preferentially expressed in certain tissues, including the
lung, mammary gland and ovary. Although the receptor
was not detected on any peripheral blood leukocyte, its
expression was induced upon the differentiation of mono-
cytes into macrophages (Hoffmann et al., 2007). CLEC12B
possesses an ITIM sequence (VxYxxL) within its cytoplas-
mic tail, which can recruit the inhibitory phosphatases,
SHP-1 and SHP-2, and, using a model system, was shown
to be able to inhibit certain cellular functions. More analysis
of CLEC12B is required to understand its physiological role.
CLEC9A
CLEC9A (which has also been termed DNGR1) is the most
recently characterized receptor from the Dectin-1 cluster
and is expressed in many tissues, as determined by RT-PCR
analysis (Caminschi et al., 2008; Huysamen et al., 2008;
Sancho et al., 2008). In peripheral blood, human CLEC9A is
found primarily on the surface of BDCA3
1 DCs, although
this receptor was also detected on small subsets of mono-
cytes and B-cells. There are at least ﬁve isoforms of CLEC9A
in mice, generated through alternative splicing, and the
receptor is expressed on CD8
1 DCs, which are thought to
be the equivalent of human BDCA3
1 cells, and also at low
levels on plasmacytoid DC. Human CLEC9A and selected
murine isoforms are expressed at the cell surface as glycosy-
lated dimers.
The cytoplasmic tail of CLEC9Acontains a single tyrosine
residue within a sequence showing similarity to the ITAM-
like sequence of Dectin-1, suggesting that CLEC9A may
function as an activation receptor. Indeed, using receptor
chimeras in transfected myeloid cells, CLEC9Awas shown to
be capable of inducing inﬂammatory cytokine production
and signal via Syk kinase (Huysamen et al., 2008). Although
this receptor did not mediate particle uptake via phagocy-
tosis, CLEC9A was capable of internalizing bound antigens
via endocytosis and directing them to the endosomal/
lysosomal pathway (Huysamen et al., 2008; Sancho et al.,
2008). Interestingly, antigens targeted to CLEC9A could
induce humoral, CD4
1 and CD8
1 T-cell responses, even in
the absence of adjuvant, suggesting that this receptor could
be exploited as a novel target on CD8
1 or BDCA3
1 DCs to
drive these responses (Caminschi et al., 2008; Sancho et al.,
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tumor antigens targeted to CLEC9A was found to elicit
potent antitumor responses (Sancho et al., 2008). However,
the ligand(s) and physiological function of this receptor are
still unknown.
CLEC-1 (CLEC1A)
Virtually nothing is known about CLEC-1, a receptor
originally identiﬁed through a computational search for
NK-related CLRs (Colonna et al., 2000). From analysis
of tissue mRNA, the human receptor was shown to be
expressed in the placenta, lung, bone marrow, thymus and
heart. At a cellular level, the receptor was detected by RT-
PCR in unstimulated as well as tumor necrosis factor (TNF)
or CD40L-stimulated DCs, and in endothelial cells. How-
ever, CLEC-1 was not detected in peripheral blood mono-
cytes (PBMCs), granulocytes, B, T, NK cells or monocytes
(Colonna et al., 2000; Sobanov et al., 2001). CLEC-1 may be
expressed in at least two isoforms, and the receptor contains
a cytoplasmic tyrosine through which it may induce intra-
cellular signaling, although this residue is not within a
recognizable signaling motif. Unlike other members of the
Dectin-1 cluster, however, CLEC-1 is not expressed at the
cell surface, at least in transfected cells.
Dectin-1 (CLEC7A)
The b-glucan receptor, Dectin-1, is one of the best char-
acterized receptors in the ‘Dectin-1 cluster’ and was origin-
ally identiﬁed as a DC-speciﬁc molecule, from which its
name ‘dendritic-cell-associated C-type lectin-1’ was derived
(Ariizumi et al., 2000; Brown, 2006). Dectin-1 is alterna-
tively spliced generating two major and a number of minor
isoforms, which have different functionalities, and the
receptor is N-glycosylated, a posttranslation modiﬁcation
that contributes to its surface expression and function.
Dectin-1 is predominantly expressed on monocytes, macro-
phages, neutrophils and microglia, but also weakly on a
subset of T cells, and in humans, B cells, mast cells and
eosinophils (Brown, 2006).
Dectin-1 speciﬁcally recognizes (1,3)-linked b-glucans in
a calcium-independent manner and is the primary receptor
for these carbohydrates on leukocytes (Brown, 2006; Palma
et al., 2006; Adams et al., 2008). The crystal structure of the
CTLD of Dectin-1 has been determined and mutational
analyses have indicated that two residues (Trp
221 and His
223)
are essentially required for b-glucan binding, and these two
residues ﬂank a groove on the CTLD that could be the
binding site (Adachi et al., 2004; Brown et al., 2007).
However, the exact mechanism of b-glucan recognition by
Dectin-1 is still unknown.
Recognition of b-glucans by Dectin-1 leads to the induc-
tion of numerous cellular responses, including the respira-
tory burst, ligand uptake by endocytosis and phagocytosis,
the production of arachidonic acid metabolites, DC matura-
tion and the induction of numerous cytokines and chemo-
kines, including TNF, CXCL2, IL-23, IL-6, IL-10 and IL-2
(Brown, 2006). Signaling from Dectin-1 is sufﬁcient for
many of these responses, but others, such as the respiratory
burst and proinﬂammatory cytokine production, require, or
are enhanced by, cooperative signaling from Myd88-coupled
TLRs (Brown, 2006; Dennehy et al., 2008). However,
the ability of Dectin-1 to induce DC maturation and the
production of cytokines, such as IL-23, can directly couple
innate and adaptive immunity, independently of the TLRs
(Leibundgut-Landmann et al., 2007). Recent data also
suggest that collaborative signaling between Dectin-1 and
MyD88-coupled TLRs is far more extensive than ﬁrst appre-
ciated, and results in the enhanced production of IL-23,
while downregulating the production of IL-12 (Gerosa
et al., 2008).
The ability of b-glucans to induce these cellular responses
is also cell-type dependent. In macrophages (Dennehy et al.,
2008), for example, particulate b-glucans are unable to
stimulate TNF production without costimulation of the
TLRs, yet in DCs, b-glucan alone is sufﬁcient to trigger the
production of this cytokine (Leibundgut-Landmann et al.,
2007). Although the underlying reasons for these differences
are not yet fully understood, they have recently been shown
to be related, in part, to phagocytosis and the actions of
cytokines, such as granulocyte monocyte colony stimulating
factor (GM-CSF) (Rosas et al., 2008).
Signaling from Dectin-1 is mediated by the cytoplasmic
tail, which contains an ITAM-like motif. Upon ligand
binding, this motif becomes tyrosine phosphorylated by Src
family kinases, leading to the recruitment of Syk, which
initiates subsequent downstream signaling pathways. The
interaction between Syk and Dectin-1 is unusual, in that it
involves only one tyrosine, and is not fully understood, but
may involve the bridging of two Dectin-1 monomers
(Rogers et al., 2005). This type of interaction is now known
to occur in at least two other Dectin-1 cluster receptors,
CLEC-2 and CLEC9A. Downstream signaling involves the
novel adaptor CARD9, as well as activation of MAP kinases,
NFAT and nuclear factor-kappa B (NFkB) (Rogers et al.,
2005; Gross et al., 2006; Goodridge et al., 2007; Slack et al.,
2007) There are also Syk-independent pathways of Dectin-1
signaling, which may be cell-type speciﬁc, but the signaling
mechanisms involved in these responses are largely unchar-
acterized (Brown, 2006).
Dectin-1 has been shown to recognize several fungal
species, including Saccharomyces, Candida, Pneumocystis,
Coccidiodes, Penicillium and Aspergillus,b u tn o tCryptococcus
(Brown, 2006; Nakamura et al., 2007, 2008). Recognition of
these organisms by Dectin-1 triggers many protective re-
sponses, such as fungal uptake by phagocytosis and killing
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production of cytokines and chemokines, and while manyof
these are known to be protective in fungal infections (such
as TNF, CXCL2, IL-1b,I L - 1 a, CCL3, GM-CSF, G-CSF and
IL-6), others (such as IL-10 and IL-23) are paradoxically
nonprotective (Brown, 2006). Although the reason for
production of these nonprotective cytokines is not yet clear,
there may be immunological beneﬁts. IL-10, for example,
inhibits antifungal immunity yet may be required to limit
inﬂammatory pathology and to promote fungal persistence
and long-term immunity.
The role of Dectin-1 has been examined in vivo, and
although the data are not entirely consistent, they support a
role for this receptor in antifungal immunity. Dectin-1-
deﬁcient mice, on a 129Sv background, displayed increased
susceptibility to systemic infection with Candida albicans,
which resulted from inﬂammatory defects and reduced
fungal killing (Taylor et al., 2007). However, Dectin-1
knockout mice on a C57BL6 background were not suscep-
tible to Candida, but were found to show differences in
fungal burdens during infection with P. carinii, which
resulted from defects in the respiratory burst (Saijo et al.,
2007). However, C57BL6 mice deﬁcient in CARD9, a down-
stream signaling component of Dectin-1, weresusceptible to
candidiasis, although this may also involve signaling path-
ways induced from other receptors (Gross et al., 2006).
Furthermore, in wild-type C57BL6 mice, inhibition of
Dectin-1 during pulmonary challenge with Aspergillus fumi-
gatus resulted in reduced lung inﬂammation and increased
fungal burden (Steele et al., 2005). In line with these
ﬁndings, differential expression of Dectin-1 isoforms in the
various mouse strains has also been linked to susceptibility
to Coccidoides (Del Pilar Jimenez et al., 2008).
Further support for a role in Dectin-1 in antifungal
immunity comes from the growing body of evidence which
indicates that fungal pathogens may actively avoid immune
recognition by masking their b-glucans (Gantner et al.,
2005). Hyphae of Aspergillus and Candida, for example, do
not expose b-glucans on their surface and enhancing
the exposure of these carbohydrates, through treatment
with caspofungin, has been shown to improve antifungal
responses (Wheeler & Fink, 2006). Other examples include
Histoplasma, which masks its b-glucan under a layer of
a-glucan, and Paracoccidioides, which switches from
b-glucan to a-glucan upon infection of the host.
Dectin-1 may also play other roles in addition to anti-
fungal immunity. Three recent publications have suggested
that Dectin-1 can recognize an unidentiﬁed ligand on
mycobacteria, promoting bacterial uptake and the induction
of a number of cytokines and chemokines, including TNF,
IL-6, RANTES and G-CSF (Yadav & Schorey, 2006;
Rothfuchs et al., 2007; Shin et al., 2008). These interactions
also induce the production of IL-12 (Rothfuchs et al., 2007),
which is of particular interest, as this T-helper type
1-promoting cytokine is essential for the control of myco-
bacterial infection.
Dectin-1 can also recognize an endogenous ligand on
T-cells, stimulating cellular activation and proliferation, and
may therefore act as a costimulatory molecule (Brown,
2006). This function of Dectin-1 is supported by its expres-
sion on antigen presenting cells in the T-cell areas of
lymphoid tissues. The recognition of the endogenous ligand
has also recently been shown to mediate the recognition
and uptake of apoptotic cells, and the cross-presentation of
cellular antigens (Weck et al., 2008). Recognition of the
endogenous ligand occurs at a distinct binding site on
Dectin-1, as its binding is not inhibitable by b-glucans.
However, the nature of the endogenous ligand, which may
be a protein, is still unknown.
Lectin-like oxidized LDL receptor (LOX-1)
(CLEC8A)
LOX-1 was the ﬁrst member of the Dectin-1 cluster to be
identiﬁed and is well characterized, being originally isolated
from a bovine aortic endothelial cDNA expression library
screenedfor receptors foroxidized LDL (OxLDL) (Sawamura
et al., 1997). LOX-1 is glycosylated, a posttranslational
modiﬁcation that contributes to cell-surface expression and
ligand recognition, and the receptor forms homodimers that
may multimerize through noncovalent interactions invol-
ving the neck region, aiding in ligand binding (Mehta et al.,
2006; Dunn et al., 2008). LOX-1 can also be prototypically
cleaved at the membrane proximal sites in the neck domain,
producing a soluble formwhose function is unknown. LOX-
1 is expressed on vascular endothelial cells, smooth muscle
cells, platelets, ﬁbroblasts and macrophages and its expres-
sion can be upregulated by a variety of proinﬂammatory,
oxidative and mechanical stimuli and during several patho-
logical conditions in vivo, such as diabetes, hyperlipidemia,
atherosclerosis and hypertension (reviewed in Chen & Du,
2007; Dunn et al., 2008). Importantly, expression of LOX-1
can also be upregulated following binding of OxLDL, which
may exacerbate the development of LOX-1-mediated dis-
eases, such as atherosclerosis.
Although a part of the Dectin-1 C-type lectin cluster,
LOX-1 is considered to be a member (class E) of the
scavenger receptor family. In addition to OxLDL, LOX-1
recognizes numerous other structurally diverse ligands in-
cluding modiﬁed lipoproteins, selected anionic polymers
and phosphopolipids, aged and apoptotic cells, activated
platelets, advanced glycation endproducts, heat shock pro-
tein (HSP)70, and gram-positive and gram-negative bacter-
ia (Chen & Du, 2007). Ligand recognition is thought to
involve electrostatic interactions with positively charged
residues that are exposed on the face of the CRD of LOX-1
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2006; Dunn et al., 2008).
Despite lacking classical signaling motifs in its cytoplasmic
tail, LOX-1 can mediate or modulate a variety of cellular
functions, including endocytosis, phagocytosis, cytokine
production, CD40 and CD40 ligand levels, apoptosis, the
activation of NFkB and production of reactive oxygen
species (Mehta et al., 2006; Chen et al., 2007; Dunn et al.,
2008). LOX-1 can also act as a cell-adhesion molecule
involved in leukocyte recruitment during inﬂammation
and, through its ability to recognize HSP70, has been
implicated in DC-mediated antigen cross-presentation
(Delneste et al., 2002; Mehta et al., 2006; Dunn et al.,
2008). Although the signaling pathways leading to these
responses are not fully understood, various downstream
components have been implicated, including phosphoinosi-
tide 3-kinase, p38 mitogen-activated protein kinase and
protein kinase Ca. Recently, LOX-1-mediated internaliza-
tion of Ox-LDL was shown to occur through a clathrin-
independent mechanism involving a novel cytoplasmic
tripeptide motif of the receptor (Murphy et al., 2008).
Much interest in LOX-1 has focused on its involvement in
vascular disease, particularly the role of this receptor in the
development of atherosclerosis. Many of the responses that
are mediated by LOX-1 have been linked to pathological,
proatherogenic, changes in the vascular endothelium, and
the upregulation of LOX-1 in atherosclerotic lesions may
result in a positive feedback loop that promotes disease
development (Mehta et al., 2006; Dunn et al., 2008). In fact,
increased release of soluble LOX-1 has been proposed to be a
marker of acute coronary syndrome. Mouse models in
which LOX-1 has been deleted, or overexpressed, also
support a role for this receptor in the development of
atherosclerosis (Inoue et al., 2005; Mehta et al., 2007; Hu
et al., 2008). Furthermore, although controversial, genetic
linkage studies have implicated human polymorphisms of
LOX-1 with susceptibility to cardiovascular disease (Mehta
et al., 2006; Dunn et al., 2008; Knowles et al., 2008). Finally
there is also evidence that LOX-1 may be involved in
thrombosis, myocardial ischemia reperfusion injury and
hypertension and thereceptormaybe involvedin generating
inﬂammatory responses during microbial infection (Mehta
et al., 2006; Hu et al., 2008).
Concluding remarks
Despite considerable similarity in structure, the Dectin-1
cluster of receptors recognizes a diverse range of structurally
unrelated ligands and mediates a wide variety of cellular
functions. While our understanding is still in its infancy, the
study of these receptors has revealed a number of new
insights into the underlying mechanisms of immunity and
homeostasis. One of the many remaining challenges is to
fully elucidate the functions and ligands of the ‘orphan’
receptors within this cluster, a task that should be greatly
aided by the generation and characterization of receptor
deﬁcient mice.
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